Patritumab deruxtecan (HER3-DXd) is an investigational DXd-conjugated ADC that has shown efficacy in patients with non-small-cell lung cancer (NSCLC) [77,78]. The gene discussed is ERBB3; the disease is non-small cell lung carcinoma.